Distinguished in Multiple Sclerosis (MS)

Caroline Bensa

Paris, FR 
Distinguished in Multiple Sclerosis (MS)
Paris, FR 
OverviewLocationsClinical Research

Overview

Caroline Bensa practices in Paris, France. Ms. Bensa is rated as a Distinguished expert by MediFind in the treatment of Multiple Sclerosis (MS). Her top areas of expertise are Multiple Sclerosis (MS), Optic Neuritis, Transverse Myelitis, and Neuromyelitis Optica.

Her clinical research consists of co-authoring 40 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 33 articles and participated in 4 clinical trials in the study of Multiple Sclerosis (MS).

Gender
Female

Locations

Paris, France
Other Locations
CHU de Toulouse
Toulouse, France
Montfermeil, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS)
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS)
Enrollment Status: Active_not_recruiting
Publish Date: August 17, 2025
Intervention Type: Drug
Study Drug: Tolebrutinib
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio®) in Participants With Relapsing Forms of Multiple Sclerosis
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio®) in Participants With Relapsing Forms of Multiple Sclerosis
Enrollment Status: Completed
Publish Date: July 02, 2025
Intervention Type: Drug
Study Drugs: Tolebrutinib, Teriflunomide HMR1726
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis
Enrollment Status: Completed
Publish Date: July 02, 2025
Intervention Type: Drug
Study Drug: Tolebrutinib
Study Phase: Phase 3
Safety of Exposure to Natalizumab During Pregnancy
Safety of Exposure to Natalizumab During Pregnancy
Enrollment Status: Completed
Publish Date: January 16, 2024
Intervention Type: Behavioral
View 3 Less Clinical Trials

40 Total Publications

Ocrelizumab-induced neutropenia: severity, recurrence, and management. A French national pharmacovigilance study.
Ocrelizumab-induced neutropenia: severity, recurrence, and management. A French national pharmacovigilance study.
Journal: Multiple sclerosis and related disorders
Published: June 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Bensa's expertise for a condition
ConditionClose
    View All 7 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile